Importantly, Ruxolitinib pre-treatment did not impact the cytotoxic capacity of tumor-infiltrating lymphocytes, as evidenced by high levels of intracellular IFN-γ (Fig. 3C) and pro-inflammatory cytokines (Fig. 3D). This evidence concerns the gene IFNG and neoplasm.